https://www.apeiron-bio.us https://www.apeiron-bio.us/pipeline https://www.apeiron-bio.us/gta182 https://www.apeiron-bio.us/research-development https://www.apeiron-bio.us/team https://www.apeiron-bio.us/about https://www.apeiron-bio.us/presentations https://www.apeiron-bio.us/news https://www.apeiron-bio.us/contact https://www.apeiron-bio.us/legal https://www.apeiron-bio.us/news/gta182-esmo-asia-2025 https://www.apeiron-bio.us/news/apeiron-therapeutics-to-present-clinical-data-on-prmt5-inhibitor-gta182-at-esmoaasia-2025-annual-congress https://www.apeiron-bio.us/news/gta182-aacr2025 https://www.apeiron-bio.us/news/gta182-aacr-2025 https://www.apeiron-bio.us/news/apeiron-enrolls-first-patient-in-phase-1ab-study-of-prmt5-inhibitor-gta182-for-mtap-deleted-solid-tumors https://www.apeiron-bio.us/news/2024oct14 https://www.apeiron-bio.us/news/2024jul18 https://www.apeiron-bio.us/news/2023oct17 https://www.apeiron-bio.us/news/2023jul10 https://www.apeiron-bio.us/news/2023apr7 https://www.apeiron-bio.us/news/2022oct27 https://www.apeiron-bio.us/news/2022mar29 https://www.apeiron-bio.us/news/2022mar18 https://www.apeiron-bio.us/news/2021jul21 https://www.apeiron-bio.us/news/2021apr16 https://www.apeiron-bio.us/news/2020feb1 https://www.apeiron-bio.us/news/2019jun1-1